Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer.

Inclusion criteria

• Male or Female age >/= 18 years of age
• Life expectancy >/= 12 weeks
• Histologically or cytologically confirmed diagnosis of HCC, unresectable advanced or metastatic
• Liver function status of Child-Pugh class A. Child-Pugh status based on clinical findings and laboratory results during the screening period
• Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1
• Patients must have at least one naïve (not previously treated by locoregional therapy) uni-dimensional measurable lesion by CT or MRI according to RECIST 1.1
• Adequate bone marrow, liver and renal function

Exclusion criteria

• Previous or concurrent cancer other than HCC, except for cervical carcinoma in situ, basal cell carcinoma, superficial bladder tumors.
• History of cardiac disease: Congestive heart failure (CHF), unstable angina, arrhythmias, Uncontrolled hypertension
• Clinically significant GI bleeding (CTCAE grade 3 or higher) within 30 days
• Renal failure requiring hemo- or peritoneal dialysis
• Known human immunodeficiency virus (HIV) infection
• Known history or symptomatic metastatic brain or meningeal tumors
• History of organ allograft.
• History of interstitial lung disease (ILD).
• Excluded previous therapies and medications:

• Prior use of systemic anti-cancer treatment for HCC including cytotoxic chemotherapy, targeted agents, or any experimental therapy
• Radiotherapy within 4 weeks prior to start of study treatment
• Any other investigational agents within 4 weeks from the first dose of study treatment
• Major surgery within 4 weeks of start of study
• Concomitant use of strong inhibitors and strong inducers of CYP3A4